Restarting the engine

After a three-week dry spell, at least three biotech IPOs are slated to price in the next two weeks. On the docket are preclinical RNAi play Alnylam - slated for Wednesday night pricing - plus Acadia and Critical Therapeutics - both slated to price early next week.

Alnylam is shooting to raise $55 million at a post-money valuation of $212 million. The company hopes to sell 5 million shares at $10-$12 through Banc of America Securities; Citigroup; Piper Jaffray; and ThinkEquity. Alnylam aims to enter the clinic next year with a VEGF inhibitor to treat wet age-related macular degeneration (AMD)...